Quadrise (LON:QED) Stock Price Up 6.1% - Here's What Happened

Key Points

• Quadrise Plc's stock price increased by 6.1% to GBX 3.50 ($0.05) during mid-day trading, despite a notable decline in trading volume.
• Insider Jason Miles sold 2.7 million shares at an average price of GBX 4, marking significant insider activity within the company.
• Quadrise, known for its disruptive heavy oil and synthetic biofuel technology, has been listed on the London Stock Exchange's AIM market since 2006.

Quadrise Plc (LON:QED - ) rose 6.1% during mid-day trading on Wednesday . The company traded as high as GBX 3.51 ($0.05) and last traded at GBX 3.50 ($0.05). Approximately 3,091,227 shares traded hands during trading, a decline of 50% from the average daily volume of 6,149,502 shares. The stock had previously closed at GBX 3.30 ($0.04).

Quadrise Stock Up 9.4%

The stock's 50 day moving average price is GBX 3.57 and its 200-day moving average price is GBX 4. The stock has a market capitalization of £72.42 million, a P/E ratio of -2,123.53 and a beta of 1.83.

Insider Activity

In other news, insider Jason Miles sold 2,702,839 shares of the stock in a transaction that occurred on Friday, July 11th. The shares were sold at an average price of GBX 4, for a total transaction of £108,113.56. Corporate insiders own 4.60% of the company's stock.

About Quadrise

Quadrise is a global innovator and licensor of the disruptive heavy oil and synthetic biofuel technology that produces its proprietary MSAR® and bioMSAR™ fuels. Quadrise employs a team of energy and fuel experts with extensive experience in commercial emulsion fuels, downstream, marine and power utility applications at a global level. Quadrise's shares have been listed on the London Stock Exchange's AIM market since 2006 AIM: QED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.